The biotech industry faces a prolonged IPO slump in 2026 as returns fail to meet expectations. With increasing investments in the sector and advancements in science, big pharma companies are likely to seek out firms with strong clinical data to offset revenue losses from expiring drug patents. Additionally, rising contract research costs are driving the […]